Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01186484 | Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer | PHASE1 | COMPLETED | 27 | — | — | Jun 1, 2010 | Oct 2, 2014 | Oct 23, 2017 | 5 | Japan |
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study. |
| Name | Type | Description |
|---|---|---|
| JNJ-212082 | DRUG | 250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study. |
Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate, but not with neuroendocrine differentiation or of small cell histology * No Prior cytotoxic chemotherapy (including estramustine) for the treatment of prostate cancer * Surgically or medically castrated,...